Bifogade filer
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från ProstaLund AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
2022-10-21 08:15:00
1 July-30 September
- Net sales reached SEK 3,8 (3,7) million
- Loss after taxes SEK -2,1 (-1,7) million
- Earnings per share were SEK -0,04 SEK (-0,03)
- Cash and equivalents were 15,9 (16,7) million
Significant events during period
- The company carried out a rights issue which brought the company approximately SEK 19.8 million in capital before issue costs
- A letter of intent regarding the distribution agreement for China is signed
- Agreement with Capio Specialistmottagning, Lund
- Distribution agreement signed for Brazil
1 January-30 September
- Net sales reached SEK 11,9 (12,1) million
- Loss after taxes SEK -8,0 (-5,7) million
- Earnings per share were SEK -0,15 SEK (-0,12)
Significant events after the end of the period
- Results for the registry study on prostate cancer are presented at the Urologidagarna in Malmö by one of the authors
- Distribution agreement signed for Spain
Key figures | ||||
(SEK MILLION) | Jan-Sep 2022 | Jan-Sep 2021 | Jan-Sep 2020 | Jan-Sep 2019 |
Net sales | 11,9 | 12,1 | 8,8 | 9,5 |
Gross margin, % | 77 | 85 | 71 | 67 |
Operating profit/loss | -7,7 | -5,6 | -6,2 | -8,1 |
Cash flow from operating activities | -13,0 | -6,3 | -6,2 | -6,6 |
Average number of employees | 7 | 7 | 5 | 5 |
“There is no longer any doubt that we have world-class products”
Johan Wennerholm
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.